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Decreasing Length of Stay in Patients Receiving High Dose Methotrexate
A Quality Improvement Project
Laura Spranklin, DO and Nicole Agostino, DO
Lehigh Valley Health Network, Allentown, PA

Goal

Decrease length of stay by
checking methotrexate levels
more frequently and changing
the methotrexate level for
discharge from <0.1µM to
<0.2µM.

Background
•	In patients receiving high dose methotrexate, the
greatest concern is renal toxicity
•	The elimination half-life of high dose methotrexate
is within the range of 8 to 15 hours
•	After IV administration, approximately 80-90% of
the methotrexate is excreted within the urine as
unchanged drug within 24 hours
•	The majority of patients will have a serum
methotrexate level <0.1µM between 24 and 48
hours
•	There is limited data detailing a safe methotrexate
level for hospital discharge and no data to support
that discharge with a methotrexate level of <0.1µM
is safer than <0.2µM
•	The cost of checking a stat serum methotrexate
level is $64.45
•	The cost of an additional night stay in the hospital is
significantly more expensive
•	It is cost effective to check methotrexate levels
twice daily in an effort to decrease length of stay in
patients receiving high dose methotrexate

Subjects
Old Protocol
− 24 hours after methotrexate
infusion is complete a
methotrexate level is checked
and leucovorin dose is based on
the methotrexate level
− Methotrexate levels are then
checked every 24 hours until
levels are <0.1µM
− When levels are <0.1µM then the
patient may be discharged on
leucovorin 15mg PO every 6
hours for a total of 24 hours

New Protocol
− 24 hours after the completion of the
methotrexate infusion, a
methotrexate level will be checked
and leucovorin started
− The methotrexate level will then be
checked twice daily, at 4:00 and
13:00 until the level is <0.2µM
− In patients with a normal creatinine
(<1.2) and normal CrCl (>60 mL/min)
or stable creatinine (no change
>0.3md/dL during the hospital stay),
once levels are <0.2µM the patient
is discharged to home and given a
script to have a methotrexate level
checked 24 hours later in the MPA to
ensure that the level is <0.1µM
− In patients with a level <0.2µM and
abnormal or unstable creatinine, they
will remain in the hospital until the
methotrexate level is <0.1µM
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•	Diagnosis included primary CNS lymphoma, peripheral T cell lymphoma, DLBCL of the testicle, T-ALL,
B-ALL, DLBCL with double hit
•	Chemotherapy regimens received included HyperCVAD, DeAngelis protocol, and high dose methotrexate
and rituxan
•	Ages of patients ranged from 27 to 79

Results
•	A total of 21 hospitalizations were reviewed prior to instituting the new protocol
•	The average length of stay was 4.47 days
•	In reviewing the 21 hospitalizations, 8 hospitalizations could have had reduced length of stay by at least
1 day implementing the new protocol
•	One hospitalization could have been reduced by 2 nights if the new protocol had been implemented
•	A total of 43 hospitalizations for high dose methotrexate were reviewed using the new protocol
•	The average length of stay with the new protocol was 3 days
•	Average LOS was reduced by 1.47 nights
•	There were 7 hospitalizations where the patient was discharged with a methotrexate level >0.1µM
•	All 7 had an outpatient methotrexate level the following day, all methotrexate levels were <0.1µM

Conclusions
•	The average length of stay was decreased by 1.47 days implementing the new protocol.
•	The new protocol is safe with regards to discharging patients with slightly higher methotrexate levels,
all repeat methotrexate levels as an outpatient were at the goal of <0.1µM
•	The new protocol for discharging patients receiving high dose methotrexate is both safe and cost
effective.
•	The new protocol is now the new standard of care in patients receiving high dose methotrexate.

